Navigation Links
Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study
Date:5/4/2009

- 12-week study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea -

NAPA, Calif., May 4 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the clinical study entitled "Topical PRK-124 (0.125%) Lotion for Improving the Signs and Symptoms of Rosacea," has been published in the May issue of Journal of Drugs in Dermatology, a peer-reviewed dermatologic publication.

"We are extremely pleased that the University of California, Irvine, study has been published in the Journal of Drugs in Dermatology," stated Frank Massino, Chairman and Chief Executive Officer of Senetek PLC. "As one of the most highly-respected and well-read publications in the dermatologic field, there is no better means to substantiate and communicate this scientific advancement to physicians interested in rosacea."

The 12-week, open-label study concludes that Pyratine XR(TM) (0.125% furfuryl tetrahydropyranyladenine) improved skin barrier function and the appearance of erythema (redness) and lesions (pustules and papules) associated with mild-to-moderate rosacea during 12 weeks of treatment.

According to study data, Pyratine XR(TM) produced a progressive decrease in the symptoms associated with rosacea, with an overall clinical improvement in 80% of subjects, including reduction of redness and lesions. Transepidermal water loss measurements showed a 22% decrease, which supports an improvement in skin barrier function, with a 41% mean improvement in skin dryness as early as week four. All subject self-assessments showed good tolerability and cosmetic acceptability.

"Current treatments for rosacea, like oral and topical antibiotics, possess long-term tolerability and other health concerns that affect the more than 14 million Americans suffering from rosacea," said Dr. Arisa Ortiz, clinical research fellow and investigator on the Pyratine XR clinical research trial. "The study data is promising for rosacea sufferers and suggests that Pyratine XR can improve rosacea symptoms without adverse effects. The findings definitely warrant further research."

To read the article in full, please visit www.jddonline.com or www.PyratineXR.com.

About Senetek PLC

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at www.senetekplc.com.


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
2. WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer
3. Study Finds Family History, Higher Incidence of Sunburns Associated With Rosacea
4. Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
5. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
6. Clinically Proven Treatment Offers Help to Rosacea Sufferers
7. Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
8. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
9. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
11. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... throughout Arkansas that offers insurance and financial preparation services, is providing an update ... City Rescue organization. , Rock City Rescue is a locally recognized nonprofit that ...
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes ... a mock evacuation of the facility as part of a disaster drill on October ... Hose EMS and Shelton City Emergency Manager, as well as the Connecticut Long ...
Breaking Medicine News(10 mins):